Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

被引：1348

作者：

Haanen, J. B. A. G. ^{[1
]}

Carbonnel, F. ^{[2
]}

Robert, C. ^{[3
]}

Kerr, K. M. ^{[4
,5
]}

Peters, S. ^{[6
]}

Larkin, J. ^{[7
]}

Jordan, K. ^{[8
]}

机构：

[1] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands

[2] Kremlin Bicetre Hosp, AP HP, Dept Gastroenterol, Paris, France

[3] Dept Med, Dermatol Unit, Roussy Canc Campus, Villejuif, France

[4] Univ Aberdeen, Sch Med, Dept Pathol, Aberdeen, Scotland

[5] Aberdeen Royal Infirm, Aberdeen, Scotland

[6] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[7] Royal Marsden Hosp NHS Fdn Trust, London, England

[8] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany

[9] ESMO Head Off, Via L Taddei 4, CH-6962 Viganello Lugano, Switzerland

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

IMMUNE CHECKPOINT BLOCKADE; CELL LUNG-CANCER; PREEXISTING AUTOIMMUNE DISORDERS; DERMATOLOGICAL ADVERSE EVENTS; ADVANCED MELANOMA; METASTATIC MELANOMA; ANTI-PD-1; THERAPY; UNTREATED MELANOMA; CLINICOPATHOLOGICAL FEATURES; ANTI-CTLA-4; ANTIBODY;

D O I：

10.1093/annonc/mdx225

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：119 / 142

页数：24

共 88 条

[1]

[Anonymous], 2016, KEYTRUDA HIGHLIGHTS, P1

[2]

[Anonymous], 2014, OPDIVO HIGHLIGHTS PR, P1

[3]

[Anonymous], 2011, YERVOY HIGHLIGHTS PR, P1

[4] Ocular and orbital side-effects of checkpoint inhibitors: a review article [J].

Antoun, Joelle ;

Titah, Cherif ;

Cochereau, Isabelle .

CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) :288-294

[5] Infliximab for IPILIMUMAB-Related Colitis-Letter [J].

Arriola, Edurne ;

Wheater, Matthew ;

Karydis, Ioannis ;

Thomas, Gareth ;

Ottensmeier, Christian .

CLINICAL CANCER RESEARCH, 2015, 21 (24) :5642-5643

[6] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[7] Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor [J].

Belum, V. R. ;

Benhuri, B. ;

Postow, M. A. ;

Hellmann, M. D. ;

Lesokhin, A. M. ;

Segal, N. H. ;

Motzer, R. J. ;

Wu, S. ;

Busam, K. J. ;

Wolchok, J. D. ;

Lacouture, M. E. .

EUROPEAN JOURNAL OF CANCER, 2016, 60 :12-25

[8] Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis [J].

Bergqvist, Viktoria ;

Hertervig, Erik ;

Gedeon, Peter ;

Kopljar, Marija ;

Griph, Hakan ;

Kinhult, Sara ;

Carneiro, Ana ;

Marsal, Jan .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (05) :581-592

[9]

Berman David, 2010, Cancer Immun, V10, P11

[10] Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab [J].

Berthod, Gregoire ;

Lazor, Romain ;

Letovanec, Igor ;

Romano, Emanuela ;

Noirez, Leslie ;

Stalder, Jessica Mazza ;

Speiser, Daniel E. ;

Peters, Solange ;

Michielin, Olivier .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :E156-E159

← 1 2 3 4 5 6 7 8 9 →